RT Journal Article
SR Electronic
T1 Tryptophan hydroxylase 1 (TPH1) Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP jpet.116.237933
DO 10.1124/jpet.116.237933
A1 Aiello, Robert J.
A1 Bourassa, Patricia-Ann
A1 Zhang, Qing
A1 Dubins, Jeffrey
A1 Goldberg, Daniel R.
A1 De Lombaert, Stephane
A1 Humbert, Marc
A1 Guignabert, Christophe
A1 Cavasin, Maria A.
A1 McKinsey, Timothy A.
A1 Paralkar, Vishwas
YR 2016
UL http://jpet.aspetjournals.org/content/early/2016/12/07/jpet.116.237933.abstract
AB Pulmonary arterial hypertension (PAH) is a progressive disease defined by a chronic elevation in pulmonary arterial pressure with extensive pulmonary vascular remodeling and perivascular inflammation characterized by an accumulation of macrophages, lymphocytes, dendritic cells and mast cells. While the exact etiology of the disease is unknown, clinical as well as pre-clinical data strongly implicate a role for serotonin (5 HT) in the process. Here, we investigated the chronic effects of pharmacological inhibition of tryptophan hydroxylase 1 (TPH1), the rate-limiting enzyme in peripheral 5 HT biosynthesis, in two pre-clinical models of pulmonary hypertension (PH), the monocrotaline (MCT) rat and the SU5416 (SUGEN)-hypoxia rat. In both PH models, KAR5585 and KAR5416, novel orally active TPH1 inhibitors with nanomolar in vitro potency, decreased serum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduced pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats. In the MCT rat model, decreases in lung 5-HT significantly correlated with reductions in histamine levels and mast cell number (p<0.001, r2=0.88). In contrast, neither ambrisentan nor tadalafil, which are vasodilators approved for the treatment of PAH, reduced mast cell number or 5-HT levels, nor were they as effective in treating the vascular remodeling as the TPH1 inhibitors. When administered in combination with ambrisentan, the TPH1 inhibitors showed an additive effect on pulmonary vascular remodeling and pressures. These data demonstrate that in addition to reducing vascular remodeling, TPH1 inhibition has the added benefit of reducing the perivascular mast cell accumulation associated with PH.